Commentary
Video
March 31, 2025
Author(s):
Conference|EBMT Meeting
Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.
Juan Carlos Hernández-Boluda, MD, PhD, an associated physician at the Hematology and Medical Oncology Service of the Hospital Clínico of Valencia, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk for patients with myelofibrosis.
Newsletter
Stay up to date on the most recent and practice-changing oncology data
Subscribe Now!
Related Videos
Dr Olivia on the Phase 3 QuANTUM-Wild Trial of Quizartinib in Newly Diagnosed FLT3-ITD–Negative AMLDr Paredes on the Association Between Fiber Intake and Improved Survival With Reduced GI aGVHD After Allo-HCTDr Wang on the Role of Menin Inhibitors in Genetically Defined AML SubtypesDr Shah on Zamtocabtagene Autoleucel’s Favorable Safety Profile in R/R DLBCLDr Lee on the Antitumor Activity of Rinatabart Sesutecan in FRα+ Platinum-Resistant Ovarian CancerDr Lantsman on the Real-World Safety and Efficacy of Dostarlimab Plus Chemo in Endometrial CancerDr Westin on PFS Benefit With DUO-E Regimen Across Histologic and Molecular pMMR Endometrial Cancer SubgroupsDr Silverstein on the Efficacy of Abemaciclib Plus Hormonal Therapy in Recurrent Low- or High-Grade Serous Ovarian CancerDr Grisham on the Efficacy of Avutometinib Plus Defactinib in Gynecologic Mesonephric CancerDr Van Gorp on the Long-Term Efficacy of Mirvetuximab Soravtansine in FRα+ Platinum-Resistant Ovarian Cancer
Related Content
ConferenceHematologic OncologyEBMT Meeting
March 31st 2025
Effective Bridging Therapy Correlates With Improved PFS After Cilta-Cel in Multiple Myeloma
March 26th 2025
Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc